NewAmsterdam Pharma Company N.V. (NAMS) shares ended the last trading session 5.9% higher at $32.48. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.6% gain over the past four weeks.The sudden rise in the stock price can be attributed to growing investor optimism regarding the potential of NewAmsterdam Pharma Company’s only investigational candidate, obicetrapib. The candidate is currently being studied as a pot ...

分组1 - Lyra Therapeutics reported a quarterly loss of $5.51 per share, which was better than the Zacks Consensus Estimate of a loss of $5.79, and an improvement from a loss of $14.5 per share a year ago, resulting in an earnings surprise of +4.84% [1] - The company posted revenues of $0.18 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 26.21%, although this was a decline from year-ago revenues of $0.6 million [2] - Lyra Therapeutics shares have declined approximately 35.4% year-to-date, contrasting with the S&P 500's gain of 8.4% [3] 分组2 - The earnings outlook for Lyra Therapeutics is mixed, with the current consensus EPS estimate for the upcoming quarter at -$6.52 on revenues of $0.15 million, and -$2.02 on revenues of $0.45 million for the current fiscal year [7] - The Zacks Industry Rank indicates that the Medical - Drugs sector is currently in the top 35% of over 250 Zacks industries, suggesting that companies in the top half tend to outperform those in the bottom half by more than 2 to 1 [8]

Company Performance - Karyopharm Therapeutics reported a quarterly loss of $4.32 per share, which was worse than the Zacks Consensus Estimate of a loss of $3.8, and compared to a loss of $3 per share a year ago, indicating a significant decline in performance [1] - The company posted revenues of $37.93 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 5.37%, and down from $42.79 million in the same quarter last year [2] - Over the last four quarters, Karyopharm has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Movement and Outlook - Karyopharm shares have lost approximately 61.1% since the beginning of the year, contrasting with the S&P 500's gain of 8.6%, indicating significant underperformance in the market [3] - The current consensus EPS estimate for the upcoming quarter is -$3.58 on revenues of $39.87 million, and for the current fiscal year, it is -$12.57 on revenues of $149.93 million [7] Industry Context - The Medical - Drugs industry, to which Karyopharm belongs, is currently ranked in the top 35% of over 250 Zacks industries, suggesting a relatively strong position within the sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Karyopharm's stock performance [5]

Company Performance - Aquestive Therapeutics reported a quarterly loss of $0.14 per share, better than the Zacks Consensus Estimate of a loss of $0.18, representing an earnings surprise of +22.22% [1] - The company posted revenues of $10 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 9.62%, and a decline from year-ago revenues of $20.1 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates just once and topped consensus revenue estimates only once [2] Stock Movement and Outlook - Shares of Aquestive Therapeutics have increased by approximately 9.6% since the beginning of the year, outperforming the S&P 500's gain of 8.6% [3] - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and future earnings expectations [3][4] - The current consensus EPS estimate for the upcoming quarter is -$0.17 on revenues of $12.33 million, and for the current fiscal year, it is -$0.72 on revenues of $45.27 million [7] Industry Context - The Medical - Drugs industry, to which Aquestive Therapeutics belongs, is currently in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact stock performance [5][6]

Company Performance - Akebia Therapeutics reported break-even quarterly earnings per share, surpassing the Zacks Consensus Estimate of a loss of $0.02, and improved from a loss of $0.04 per share a year ago, resulting in an earnings surprise of +100.00% [1] - The company posted revenues of $62.47 million for the quarter ended June 2025, exceeding the Zacks Consensus Estimate by 33.50%, compared to year-ago revenues of $43.65 million [2] - Over the last four quarters, Akebia has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Performance - Akebia Therapeutics shares have increased approximately 99.2% since the beginning of the year, significantly outperforming the S&P 500's gain of 7.9% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.03 on revenues of $46.52 million, and for the current fiscal year, it is -$0.05 on revenues of $199.75 million [7] Industry Outlook - The Medical - Drugs industry, to which Akebia belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, suggesting that the industry outlook can materially impact stock performance [5][8]

Group 1 - Catalyst Pharmaceutical (CPRX) reported quarterly earnings of $0.68 per share, exceeding the Zacks Consensus Estimate of $0.58 per share, and showing an increase from $0.56 per share a year ago, resulting in an earnings surprise of +17.24% [1] - The company achieved revenues of $146.56 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 5.30%, and up from $122.71 million in the same quarter last year [2] - Catalyst has consistently surpassed consensus EPS estimates for the last four quarters, indicating strong performance [2] Group 2 - The stock has gained approximately 6.5% since the beginning of the year, compared to the S&P 500's gain of 7.1%, suggesting a slight underperformance relative to the broader market [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The Zacks Rank for Catalyst is currently 2 (Buy), indicating expectations for the stock to outperform the market in the near future [6] Group 3 - The current consensus EPS estimate for the upcoming quarter is $0.56 on revenues of $138.29 million, while for the current fiscal year, the estimate is $2.25 on revenues of $559.96 million [7] - The Medical - Drugs industry, to which Catalyst belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable industry outlook [8]

Company Overview - Harrow (HROW) is expected to report a year-over-year increase in earnings due to higher revenues for the quarter ended June 2025, with a consensus EPS estimate of $0.00 per share, indicating a +100% change [1][3] - Revenues are projected to be $65.32 million, reflecting a 33.5% increase from the same quarter last year [3] Earnings Expectations - The upcoming earnings report is anticipated to be released on August 11, and the stock may rise if actual results exceed expectations, while a miss could lead to a decline [2] - The consensus EPS estimate has been revised down by 7.89% over the last 30 days, indicating a bearish sentiment among analysts [4] Earnings Surprise Prediction - The Most Accurate Estimate for Harrow is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -1,000.01%, which complicates predictions of an earnings beat [12] - Harrow currently holds a Zacks Rank of 3, suggesting a neutral outlook [12] Historical Performance - In the last reported quarter, Harrow was expected to post earnings of $0.02 per share but instead reported a loss of -$0.38, resulting in a surprise of -2,000.00% [13] - Over the past four quarters, Harrow has beaten consensus EPS estimates two times [14] Industry Context - Aclaris Therapeutics (ACRS), another player in the Zacks Medical - Drugs industry, is expected to report a loss of $0.13 per share for the same quarter, indicating a year-over-year change of +13.3% [18] - Aclaris's revenues are expected to be $1.55 million, down 44% from the previous year, with a consensus EPS estimate revised 1.4% higher recently [19]

Core Viewpoint - Ionis Pharmaceuticals reported a quarterly earnings of $0.86 per share, significantly exceeding the Zacks Consensus Estimate of $0.27 per share, and showing a substantial improvement from a loss of $0.45 per share a year ago [1] Financial Performance - The company achieved revenues of $452 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 66.96%, compared to $225 million in the same quarter last year [2] - Over the last four quarters, Ionis Pharmaceuticals has consistently exceeded consensus EPS estimates [2] Stock Performance - Ionis Pharmaceuticals shares have increased approximately 18.7% since the beginning of the year, outperforming the S&P 500's gain of 8.3% [3] Future Outlook - The company's earnings outlook will be crucial for assessing future stock performance, including current consensus earnings expectations for upcoming quarters [4] - The current consensus EPS estimate for the next quarter is -$0.94 on revenues of $162.43 million, and for the current fiscal year, it is -$2.41 on revenues of $742.14 million [7] Industry Context - The Medical - Drugs industry, to which Ionis Pharmaceuticals belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook compared to lower-ranked industries [8]

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell even higher, with the expectation that established trends will continue [1][2]. Company Overview: Grifols (GRFS) - Grifols currently holds a Momentum Style Score of A, indicating strong momentum potential [3]. - The company has a Zacks Rank of 2 (Buy), suggesting it is positioned for outperformance in the market [4]. Performance Metrics - Over the past week, Grifols shares increased by 2.47%, while the Zacks Medical - Drugs industry remained flat [6]. - In a longer timeframe, Grifols' shares have risen by 15.44% over the past month, significantly outperforming the industry's 3.53% [6]. - For the past quarter, Grifols shares increased by 8.89%, and over the last year, they gained 15.12%, compared to the S&P 500's 3.59% and 14.21% respectively [7]. Trading Volume - Grifols has an average 20-day trading volume of 819,084 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In the last two months, one earnings estimate for Grifols has increased, while none have decreased, raising the consensus estimate from $0.96 to $0.99 [10]. - For the next fiscal year, one estimate has also moved upwards with no downward revisions [10]. Conclusion - Given the strong performance metrics and positive earnings outlook, Grifols is recommended as a solid momentum pick for investors [11][12].

Group 1: Earnings Performance - Verve Therapeutics reported a quarterly loss of $0.35 per share, significantly better than the Zacks Consensus Estimate of a loss of $0.71, representing an earnings surprise of 50.70% [1] - The company has surpassed consensus EPS estimates in all four of the last quarters [2] - The revenue for the quarter ended March 2025 was $32.98 million, exceeding the Zacks Consensus Estimate by 362.76%, compared to $5.7 million in the same quarter last year [2] Group 2: Stock Performance and Outlook - Verve Therapeutics shares have declined approximately 26.2% since the beginning of the year, while the S&P 500 has gained 0.1% [3] - The company's earnings outlook is mixed, with the current consensus EPS estimate for the upcoming quarter at -$0.70 on revenues of $8.29 million, and for the current fiscal year at -$2.73 on revenues of $29.74 million [7] - The Zacks Rank for Verve Therapeutics is currently 3 (Hold), indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Drugs industry, to which Verve Therapeutics belongs, is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Plus Therapeutics, is expected to report a quarterly loss of $0.17 per share, reflecting a year-over-year change of +77.3% [9]